Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
2000 2
2001 2
2002 2
2004 1
2006 3
2007 5
2008 3
2009 5
2012 1
2013 2
2014 4
2015 8
2016 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O. Genovese MC, et al. Among authors: berclaz py. Ann Rheum Dis. 2013 Sep 1;72(9):1453-60. doi: 10.1136/annrheumdis-2012-202864. Epub 2013 Apr 18. Ann Rheum Dis. 2013. PMID: 23599435 Clinical Trial.
GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis.
Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, Puchalski JT, Hauck DM, Trapnell BC. Uchida K, et al. Among authors: berclaz py. N Engl J Med. 2007 Feb 8;356(6):567-79. doi: 10.1056/NEJMoa062505. N Engl J Med. 2007. PMID: 17287477 Free article.
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
Smolen JS, Weinblatt ME, van der Heijde D, Rigby WF, van Vollenhoven R, Bingham CO 3rd, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz PY, Ortmann R, Lee C. Smolen JS, et al. Among authors: berclaz py. Ann Rheum Dis. 2015 Aug;74(8):1567-70. doi: 10.1136/annrheumdis-2014-207090. Epub 2015 Apr 14. Ann Rheum Dis. 2015. PMID: 25873635 Clinical Trial.
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, Heffernan M. Saeki H, et al. Among authors: berclaz py. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1148-55. doi: 10.1111/jdv.12773. Epub 2014 Oct 30. J Eur Acad Dermatol Venereol. 2015. PMID: 25355284 Clinical Trial.
36 results